Easom Eric's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Oct 24, 2022
- Accession no.
- 0000899243-22-034092
- Filed
- Oct 24, 2022
- Trade date
- Oct 20-21, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $349.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Easom EricCIK 0001914503 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 20, 2022 | Common Stock | SSaleDisposed | −7,262 | $16.68 | −$121,130.16 | 18,889 | Direct | |
| Oct 20, 2022 | Common Stock | SSaleDisposed | −31 | $17.15 | −$531.65 | 18,858 | Direct | |
| Oct 21, 2022 | Common Stock | SSaleDisposed | −11,601 | $16.29 | −$188,980.29 | 7,257 | Direct | |
| Oct 21, 2022 | Common Stock | SSaleDisposed | −2,350 | $16.69 | −$39,221.5 | 4,907 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.